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Abstract
Purpose The aim of this study was to assess the measure-
ment properties of the 5-level classification system of the
EQ-5D (5L), in comparison with the 3-level EQ-5D (3L).
Methods Participants (n = 3,919) from six countries,
including eight patient groups with chronic conditions (car-
diovascular disease, respiratory disease, depression, diabetes,
liver disease, personality disorders, arthritis, and stroke) and a
student cohort, completed the 3L and 5L and, for most par-
ticipants, also dimension-specific rating scales. The 3L and 5L
were compared in terms of feasibility (missing values),
redistribution properties, ceiling, discriminatory power, con-
vergent validity, and known-groups validity.
Results Missing values were on average 0.8 % for 5L and
1.3 % for 3L. In total, 2.9 % of responses were inconsistent
between 5L and 3L. Redistribution from 3L to 5L using EQ
dimension-specific rating scales as reference was validated for
all 35 3L–5L-level combinations. For 5L, 683 unique health
states were observed versus 124 for 3L. The ceiling was
reduced from 20.2 % (3L) to 16.0 % (5L). Absolute discrimi-
natory power (Shannon index) improved considerably with 5L
(mean 1.87 for 5L versus 1.24 for 3L), and relative discrimi-
natory power (Shannon Evenness index) improved slightly
(mean 0.81 for 5L versus 0.78 for 3L). Convergent validity with
WHO-5 was demonstrated and improved slightly with 5L.
Known-groups validity was confirmed for both 5L and 3L.
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Conclusions The EQ-5D-5L appears to be a valid extension
of the 3-level system which improves upon the measurement
properties, reducing the ceiling while improving discriminatory
power and establishing convergent and known-groups validity.
Keywords EQ-5D  Health-related quality of life 
Psychometrics  Patient-reported outcomes 
Utility assessment
Introduction
As a generic preference-based measure of health, the EQ-5D
has many applications that aid decision making in health care
[1]. The standard format of the EQ-5D descriptive classifi-
cation system developed by the EuroQoL Group consists of
five dimensions of health, each with three levels of problems
(EQ-5D-3L, hereafter ‘‘3L’’). Over the past twenty years,
value sets for the 3L health classification system have been
developed for many countries around the world [2].
There is an extensive body of literature to support the
validity and reliability of the 3L descriptive system, the
EQ-VAS, and the 3L index values in many conditions and
populations [3–8]. However, its restricted ability to dis-
criminate small to moderate differences in health status has
been questioned widely [9–12]. Moreover, several studies
reported a ceiling effect of the 3L in both general popu-
lation and patient settings [13–18].
The EuroQol Group has recently introduced a 5-level
EQ-5D (EQ-5D-5L, hereafter ‘‘5L’’), which expands the
range of responses in each dimension from three to five levels
[19]. Preliminary studies indicated that prototype 5L versions
improved upon the properties of the 3L in terms of reduced
ceiling effects, increased reliability, and improved ability to
discriminate between different levels of health [20–22].
A Korean study has shown good measurement properties
for the 5L in cancer patients [23]. To our knowledge, there
has been no validation of other language versions of EQ-5D-
5L, nor has there been assessment of measurement properties
in other patient groups or a combination of patients groups.
The goal of this study was to assess the measurement prop-
erties of the 5L, in comparison with the 3L, across a wide
range of patient groups. The specific aims were to evaluate
and compare the properties of 3L and 5L in terms of feasi-
bility (missing values), consistent redistribution of responses
from 3L to 5L, ceiling, discriminatory power (Shannon
indices), convergent validity, and known-groups validity.
Methods
Data
This study aimed at assessing measurement properties for
3L and 5L in eight broad patient groups. A student cohort
was added in order to investigate how both instruments
perform in a healthy population sample. Respondents
completed both the 3L and 5L in six countries: Denmark,
England, Italy, the Netherlands, Poland, and Scotland. Data
collection in Denmark was conducted through the endo-
crinology, rheumatology, and orthopedic departments of a
regional university hospital. Data collection in England
was organized through a specialist patient recruitment
agency and aimed at patients with prespecified conditions.
In Italy the cohort of liver disease patients completed the
questionnaires locally at two hospitals (Bergamo and
Naples). Data collection in the Netherlands was conducted
at a specialist center for personality disorders and at a local
hospital for the kidney dialysis patients. In Poland, the
student cohort was recruited at the Medical University of
Warsaw in Poland, and the stroke cohort was recruited
through the Neurological Clinic in Warsaw. Data collection
in Scotland took place through a specialist patient
recruitment agency, with patients completing the ques-
tionnaires at primary care centers. Paper and pencil ver-
sions of the questionnaires were used in all countries
except in England where data collection took place online.
Data collection took place between August 2009 and
September 2010. The 5L was administered first, followed
by the EQ-5D visual analogue scale (EQ-VAS) and a
number of demographic questions, then the 3L, and finally
a set of five dimension-specific rating scales. All respon-
dents scored 5L first, as a previous study showed a ten-
dency to avoid the in-between levels 2 and 4 of 5L when
responding to the 3L first [20]. Data collection was
undertaken with informed consent and according to the
ethical guidelines for health research in each country.
Measures
The 3L version of the EQ-5D is the initial version that has
been used in many clinical trials and methodological
studies published in the peer-reviewed literature [1]. It is a
brief self-reported generic measure of current health that
consists of five dimensions (Mobility, Self-Care, Usual
Activities, Pain/Discomfort, and Anxiety/Depression), each
with three levels of functioning (no problems, some prob-
lems, and unable to/extreme problems). This health state
classification describes 243 unique health states that are
often reported as vectors ranging from 11111 (full health)
to 33333 (worst health). Societal value sets have been
derived from population-based valuation studies around the
world that, when applied to the health state vectors, result
in preference-based index values that typically range from
states worse than dead (\0), to 1 (full health), anchoring
dead at 0. In addition, the EQ-5D includes an EQ-VAS
where own health ‘‘today’’ is rated on a scale from 0 (worst
imaginable health) to 100 (best imaginable health).
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In developing the 5L, the five-dimensional structure of the
3L was retained, but the descriptors within each dimension
were adapted to a 5-level system based on qualitative and
quantitative studies conducted by the EuroQol group [19].
The labels for 5L followed the format no problems, slight
problems, moderate problems, severe problems, and unable
to/extreme problems for all dimensions. For Mobility, the
description of ‘‘confined to bed’’ was changed to ‘‘unable to
walk about.’’ Additionally, for Usual Activities, the word
‘‘performing’’ was changed to ‘‘doing’’ (English for UK
version). The official EQ-5D-3L and EQ-5D-5L language
versions for each country were used.
For the purposes of the current study, respondents also
rated their own health ‘‘today’’ on five dimension-specific
rating scales, one for each of the EQ-5D dimensions. Each
scale consisted of a horizontal hash-marked line (from 0 to
100) with corresponding numbers (0, 10, 20, …, 100). The
descriptive anchors at each end of the scales were the same
anchors as used in the 3L and 5L, that is, no problems and
unable to/extreme problems.
Convergent validity was assessed by comparing the 3L
and 5L dimensions to the WHO-5 Well Being questionnaire.
The WHO-5 captures well-being and was developed from
the World Health Organization-Ten Well-Being Index [24,
25]. It was conceptualized as a unidimensional measure that
contains five positively worded items: ‘‘I have felt cheerful
and in good spirits’’; ‘‘I have felt calm and relaxed’’; ‘‘I have
felt active and vigorous’’; ‘‘I woke up feeling fresh and res-
ted’’; and ‘‘My daily life has been filled with things that
interest me,’’ all operationalized using a six-point Likert
scale ranging from 0 (not present) to 5 (constantly present).
A sum-score can be calculated as a summary measure.
Analysis
Feasibility was assessed by calculating the number of
missing values for 3L and 5L. The ceiling of the EQ-5D
was defined as the proportion of respondents scoring no
problems on any of the five dimensions, that is, the pro-
portion of respondents scoring 11111. Under the assump-
tion that the majority of patients should have at least some
problem on at least one of the EQ-5D dimensions, we
expect the ceiling to be lower for 5L compared to 3L. An
absolute reduction when going from 3L to 5L was calcu-
lated, but since the ceiling was very small in some patient
groups, a percentage reduction was also calculated: (ceil-
ing3L - ceiling5L)/ceiling3L.
Redistribution properties of the 3L to 5L extension
Redistribution properties and (in)consistency of responses
were evaluated using criteria established in previous studies
[20, 21]. An inconsistent response was defined as a 3L
response followed by a 5L response that was at least two
levels away. The redistribution properties of the consistent
response pairs were described as proportions of the 3L–5L
response pairs within each 3L response level (3L-1, 3L-2,
and 3L-3) and corresponding dimension-specific rating
scale values. For valid redistribution, dimension-specific
rating scale values should be increasing when going from
the ‘‘healthiest’’ response pair (3L-1 paired with 5L-1) to
the most extreme response pair (3L-3 paired with 5L-5).
Discriminatory power
The Shannon index and the Shannon Evenness index were
used to assess discriminatory power. Originating from the
field of information theory, the Shannon index has been
widely used in ecological studies as a measure of biodi-
versity and in molecular biology as a measure of the
information content of DNA molecules [26–28]. Previous
research showed Shannon’s methodology to be useful in
assessing discriminatory power in health state classifica-
tions [20, 21, 23, 29, 30]. In the present study, we estimated
discriminatory power for each dimension separately. The





where H0 represents the absolute amount of informativity
captured, L is the number of levels, and pi = ni/N, the pro-
portion of observations in the ith level (i = 1,…, L), where ni
is the observed number of scores (responses) in level i and
N is the total sample size [31]. The higher the index H0 is, the
more information is captured by the system. In the case of a
uniform (rectangular) distribution (i.e., pi = p* for all i),
the optimal amount of information is captured and H0 has
reached its maximum (H0max) which equals log2 L. If the
number of levels (L) is increased, H0max increases accord-
ingly, but H0 will only increase if the newly added levels are
actually used. Shannon Evenness index (J0) exclusively
reflects the evenness (rectangularity) of a distribution,
regardless of the number of levels. Shannon Evenness index
(J0) is defined as: J0 = H0/H0max. The Shannon indices are
calculated by dimension and also by instrument as a whole,
treating each health state vector as a unique category.
The Shannon indices are purely descriptive measures of
the discriminatory power of a classification system and have
no relation to the content, meaning, or clinical relevance of
what the instrument aims to measure. Both the Shannon
index and the Shannon Evenness index are needed to make a
useful interpretation of the discriminatory power of a mea-
surement scale. Consider any 3L and 5L dimension: Clearly,
the 5L has more discriminatory potential. However, if the
extra levels are not used, the H0 value will be the same in both
Qual Life Res (2013) 22:1717–1727 1719
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dimensions. Therefore, the Shannon Evenness index J0,
which will be lower, is needed to express the loss in potential
of the 5-level dimension. Conversely, when both the 3L and
5L show rectangular distributions, the J0 value will be the
same. In this case, H0 is needed to express the better dis-
criminatory performance of the 5L. We expected H0 to
increase and J0 to marginally decrease at most.
Convergent validity
Convergent validity between the 3L and 5L dimensions
and the WHO-5 items was assessed using Spearman rank
order coefficients (Spearman’s rho), including a compari-
son with the WHO-5 sum-score. We hypothesized corre-
lations to be highest for WHO-5 items with Anxiety/
Depression. Convergence of 3L and 5L with dimension-
specific rating scales was also assessed.
Known-groups validity
Known-groups validity was tested for all 3L and 5L
dimensions in regard to age, education, and smoking status.
Tests for age-groups (18–24, 35–44, 45–54, 55–64, 65–74,
and 75?) and education were performed using Spearman
rank order coefficients, and smoking status (never smoked,
ex-smoker, and current smoker) was assessed with the
Kruskall–Wallis H statistic. Education was included in
three substudies (England, Denmark, and Scotland) and
was recoded into three levels (1 = primary/lower second-
ary; 2 = secondary/vocational; 3 = higher/college). In
regard to known-groups validity, we expected a lower
reported health status for respondents with increasing age,
lower education, and respondents who smoke or have
smoked. In order to take possible clustering effects into
account, we applied a set of statistical techniques devel-
oped for nonparametric statistics for clustered data, with
country as cluster variable [32, 33].
The study data were analyzed centrally using PASW
version 18.0.0 and R version 2.15.2.
Results
In total, 3,919 respondents completed both the 3L and 5L
(Table 1). The overall cohort was 52 % female and had a
mean age of 51.9 (standard deviation (SD) 20). A mean
(SD) EQ-VAS score of 64 (23) was observed, ranging from
41 (30) for Parkinson’s disease to 79 (16) for the student
sample. For 5L, 683 unique health states were observed
(22 % of the total number of theoretically possible health
states) versus 124 for 3L (51 % of the total).
Respondents were classified into nine different sub-
groups that included cardiovascular disease (n = 251),
COPD/asthma (n = 342), depression (n = 250), diabetes
(n = 284), liver disease (n = 645), personality disorders
(n = 384), rheumatoid arthritis/arthritis (n = 372),
stroke (n = 614), and students (n = 443). Less prevalent
conditions listed in Table 1 were collapsed into an ‘‘other
conditions’’ category (n = 334). The average number of
unique health states by subgroup was 49 for 3L ranging
from 16 (student population) to 73 (stroke patients), and 158
for 5L ranging from 49 (student population) to 280 (stroke
cohort).
Table 1 Characteristics and descriptive results of study sample by
country and patient group








Denmark Diabetes 239 45 52.9 74 (19)
Orthopedic
accident
94 34 37.8 79 (23)
Rheumatoid
arthritis
35 73 60.5 60 (25)
England ADHD 69 54 34.3 63 (21)
Arthritis 250 44 57.7 66 (20)
Back pain 70 57 47.2 52 (19)
COPD 125 37 60.8 57 (21)
Depression 250 56 42.4 62 (21)
Diabetes 45 58 50.8 69 (20)
Myocardial
infarction
75 27 56.7 63 (20)
Parkinson’s
disease
32 44 49.8 66 (22)
Stroke 85 39 57.4 53 (24)
Italy Liver disease 645 35 56.7 70 (21)
Netherlands Kidney dialysis 49 41 61.7 62 (21)
Personality
disorders
384 67 31.7 59 (18)
Poland Stroke 529 49 69.9 52 (26)
Student
population
443 79 22.1 79 (16)
Scotland Asthma 21 57 72.8 64 (18)
Cardiovascular
disease
176 54 71.4 60 (21)
COPD 196 62 70.1 58 (21)
Multiple
sclerosis
15 53 63.9 52 (21)
Parkinson’s
disease
5 60 63.0 41 (30)
Rheumatoid
arthritis
87 71 69.4 56 (22)
Total 3,919 52 51.9 64 (23)
ADHD attention-deficit/hyperactivity disorder, COPD chronic
obstructive pulmonary disease, EQ-VAS EQ-5D visual analogue
scale, where respondent rated own health on a scale from 0 (worst
imaginable health) to 100 (best imaginable health)
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Missing values ranged from 43 for Mobility (1.1 %) to
57 for Pain/Discomfort (1.5 %) for 3L and from 19 for
Mobility (0.5 %) to 37 for Usual Activities (0.9 %) for 5L.
Missing values were on average 0.8 % for 5L and 1.3 %
for 3L, indicating good feasibility for both instruments.
Cross tabulations of responses to the 3L and 5L, which
include all data, showed that participants reported a wide
range of level of health within each of the EQ-5D dimen-
sions (Table 2). The areas shaded gray in Table 2 show the
inconsistent responses. The number of inconsistencies was
highest in Pain/Discomfort (n = 130; 3.4 %) and lowest in
Mobility (n = 82; 2.1 %). The average proportion of
inconsistencies by dimension was 2.9 %.
Table 3 shows 3L and 5L dimension responses for the
eight patient groups and the student cohort. Overall, 5L
responses show a good spread for most dimensions and
patient samples, revealing the benefit of the extra levels in
the 5L. The responses in Mobility show the effect of
changing the most extreme level from ‘‘confined to bed’’ to
‘‘unable to walk about,’’ as respondents make better use of
the 5L scale.
Redistribution from 3L to 5L using the dimension-spe-
cific rating scales as reference showed valid results for all
35 3L–5L (consistent) level combinations, as the mean
rating scale scores decreased when going from the health-
iest subgroup to the most disabled subgroup, regardless of
dimension (Table 4). Proportions (% by level) show con-
siderable variation across dimensions. For the 3L–1 sub-
groups of each dimension, there was always a higher
proportion in 5L–1 than in 5L–2. The most skewed relative
frequency distribution was in Self-Care (97/3) and the least
in Pain/Discomfort (86/14). The 3L–2 subgroups showed
variable proportions per dimension; the most evenly spread
proportion was in Mobility (37/38/25) and the most
unevenly spread in Anxiety/Depression (50/41/9). The 5L–
4 scores always corresponded with the lowest proportion for
Table 2 Cross tabulation for EQ-5D-3L and EQ-5D-5L dimension scores (inconsistent responses are marked with italicized values)
3L 5L
Mobility No problems Slight problems Moderate problems Severe problems Unable to
No problems 1,941 121 16 1 4
Some problems 32 588 598 393 23
Confined to bed 1 1 4 30 112
3L 5L
Self-Care No problems Slight problems Moderate problems Severe problems Unable to
No problems 2,653 83 13 5 0
Some problems 48 425 321 110 6
Unable to 3 5 6 35 141
3L 5L
Usual Activities No problems Slight problems Moderate problems Severe problems Unable to
No problems 1,527 167 22 9 0
Some problems 49 686 676 277 16
Unable to 5 7 24 140 242
3L 5L
Pain/Discomfort None Slight Moderate Severe Extreme
None 1,251 211 21 6 2
Moderate 67 895 869 244 9
Extreme 1 5 19 160 83
3L 5L
Anxiety/Depression None Slight Moderate Severe Extreme
None 1,466 220 31 10 3
Moderate 46 890 731 165 7
Extreme 1 4 17 163 94
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Table 3 Dimension responses for EQ-3D-3L and EQ-3D-5L across eight patient groups and a student cohort
Level Mobility Self-Care Usual Activities Pain/Discomfort Anxiety/Depression
3L 5L 3L 5L 3L 5L 3L 5L 3L 5L
N % N % N % N % N % N % N % N % N % N %
Cardiovascular
disease
1 70 28 56 22 145 58 136 54 75 30 64 25 74 29 64 25 126 50 110 44
2 179 71 60 24 94 37 61 24 135 54 57 23 151 60 71 28 111 44 70 28
3 2 1 74 29 12 5 35 14 41 16 67 27 26 10 61 24 14 6 51 20
4 – – 56 22 – – 12 5 – – 42 17 – – 45 18 – – 14 6
5 – – 5 2 – – 7 3 – – 21 8 – – 10 4 – – 6 2
COPD/Asthma 1 85 25 72 21 203 59 192 56 89 26 76 22 79 23 76 22 177 52 163 48
2 255 75 80 23 129 38 70 20 213 62 91 27 214 63 88 26 143 42 81 24
3 2 1 94 27 10 3 52 15 40 12 87 25 49 14 105 31 22 6 74 22
4 – – 90 26 – – 19 6 – – 66 19 – – 60 18 – – 20 6
5 – – 6 2 – – 9 3 – – 22 6 – – 13 4 – – 4 1
Depression 1 165 66 154 62 205 82 204 82 119 48 113 45 107 43 82 33 46 18 33 13
2 84 34 54 22 44 18 21 8 118 47 72 29 121 48 88 35 175 70 89 36
3 1 0 24 10 1 0 21 8 13 5 37 15 22 9 48 19 29 12 80 32
4 – – 17 7 – – 4 2 – – 25 10 – – 24 10 – – 32 13
5 – – 1 0 – – 0 0 – – 3 1 – – 8 3 – – 16 6
Diabetes 1 189 68 179 64 232 83 231 83 172 61 162 58 129 47 115 42 189 68 173 62
2 89 32 53 19 47 17 36 13 95 34 69 25 135 49 93 34 87 31 71 26
3 0 0 26 9 0 0 8 3 13 5 28 10 13 5 41 15 3 1 25 9
4 – – 21 8 – – 4 1 – – 13 5 – – 23 8 – – 7 3
5 – – 0 0 – – 0 0 – – 6 2 – – 5 2 – – 1 0
Liver disease 1 457 74 465 73 542 88 568 89 425 68 428 68 367 60 365 58 346 56 347 55
2 163 26 103 16 73 12 42 7 183 29 106 17 233 38 151 24 249 40 166 26
3 1 0 53 8 3 0 21 3 14 2 69 11 15 2 94 15 22 4 97 15
4 – – 17 3 – – 4 1 – – 22 3 – – 19 3 – – 19 3
5 – – 1 0 – – 2 0 – – 6 1 – – 3 0 – – 5 1
Personality disorder 1 324 85 320 84 357 94 357 93 120 31 98 26 168 44 137 36 64 17 51 13
2 58 15 39 10 24 6 21 5 228 60 85 22 197 52 132 34 217 57 82 21
3 1 0 21 5 0 0 3 1 33 9 119 31 17 4 85 22 100 26 119 31
4 – – 2 1 – – 1 0 – – 70 18 – – 26 7 – – 105 27
5 – – 1 0 – – 0 0 – – 10 3 – – 3 1 – – 25 7
RA/Arthritis 1 106 29 83 22 235 64 223 60 106 29 81 22 45 12 26 7 222 60 190 51
2 263 71 115 31 132 36 84 23 232 63 131 36 282 76 123 33 134 36 100 27
3 0 0 101 27 3 1 43 12 32 9 94 25 43 12 135 37 14 4 54 15
4 – – 67 18 – – 17 5 – – 46 12 – – 73 20 – – 18 5
5 – – 3 1 – – 2 1 – – 17 5 – – 12 3 – – 7 2
Stroke 1 133 22 121 20 201 33 190 31 118 20 108 18 122 20 117 19 141 23 122 20
2 359 59 117 19 263 44 122 20 309 51 127 21 428 71 148 25 416 69 213 35
3 115 19 160 26 139 23 117 19 176 29 141 23 50 8 212 35 46 8 169 28
4 – – 113 19 – – 60 10 – – 95 16 – – 100 17 – – 79 13
5 – – 99 16 – – 118 19 – – 133 22 – – 26 4 – – 22 4
Students 1 434 98 428 97 442 100 442 442 398 90 376 85 297 67 268 60 246 56 190 43
2 9 2 12 3 1 0 0 1 44 10 48 11 145 33 143 32 192 43 173 39
3 0 0 2 0 0 0 1 0 1 0 15 3 1 0 29 7 5 1 55 12
4 – – 1 0 – – 0 0 – – 3 1 – – 3 1 – – 21 5
5 – – 0 0 – – 0 0 – – 1 0 – – 0 0 – – 4 1
COPD chronic obstructive pulmonary disease, RA rheumatoid arthritis
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3L–2. The 3L–3 scores corresponded with the largest pro-
portion in 5L–5 for the first three dimensions, but were
associated with more 5L–4 scores in the case of Pain/Dis-
comfort and Anxiety/Depression.
The ceiling by disease subgroup and by country is
shown in Table 5. The reduction in ceiling going from 3L
to 5L varied considerably over subgroups and countries,
ranging from an absolute reduction of 1.1 % for stroke
patients to 12.6 % for the student cohort. Percentage
reduction ranged from 7.1 % for the Danish population to
49.0 % for the Dutch population. On average, the ceiling
was reduced from 20.2 % (3L) to 16.0 % (5L), an absolute
reduction of 4.2 % and a percentage reduction of 20.8 %.
Overall, the ceiling was reduced the least for the Danish
and Italian population samples.
Absolute discriminatory power (Shannon index) showed
a substantial gain in information richness by using the 5L
classification system for all dimensions and the overall
classification system (H05L/H03L): Mobility (1.89/1.19);
Self-Care (1.42/1.05); Usual Activities (2.08/1.39); Pain/
Discomfort (2.01/1.28); Anxiety/Depression (1.96/1.30);
and overall (4.8/7.2). Relative discriminatory power
(Shannon Evenness index) improved slightly for most
dimensions and the overall system (J05L/J03L): Mobility
(0.81/0.75); Self-Care (0.61/0.66); Usual Activities (0.89/
0.88); Pain/Discomfort (0.87/0.81); Anxiety/Depression
Table 4 Redistribution
properties from EQ-5D-3L to
EQ-5D-5L: consistent responses
a Dimension-specific rating
scale values were only available
for a subset of respondents
(without the student and liver
disease samples); respondents
rated own level of health by
dimension on scales from 0
(worst) to 100 (best)
Dimension 3L n % by dimension 5L n % by level Rating scale meana
Mobility 1 2,083 53.9 1 1,941 94.1 96.8
2 121 5.9 84.5
2 1,634 42.3 2 588 37.2 70.0
3 598 37.9 52.4
4 393 24.9 32.1
3 148 3.8 4 30 21.1 16.6
5 112 78.9 3.1
Self-Care 1 2,754 71.5 1 2,653 97.0 98.0
2 83 3.0 81.6
2 910 23.6 2 425 49.6 68.6
3 321 37.5 49.4
4 110 12.9 32.9
3 190 4.9 4 35 19.9 18.2
5 141 80.1 6.1
Usual Activities 1 1,725 44.8 1 1,527 90.1 96.7
2 167 9.9 86.8
2 1,704 44.3 2 686 41.9 72.4
3 676 41.2 53.1
4 277 16.9 36.9
3 418 10.9 4 140 36.6 20.1
5 242 63.4 8.8
Pain/Discomfort 1 1,491 38.8 1 1,251 85.6 95.7
2 211 14.4 84.4
2 2,084 54.2 2 895 44.6 72.5
3 869 43.3 54.5
4 244 12.2 37.2
3 268 7.0 4 160 65.8 21.8
5 83 34.2 13.0
Anxiety/Depression 1 1,730 45.0 1 1,466 87.0 97.2
2 220 13.0 84.6
2 1,839 47.8 2 890 49.8 66.4
3 731 40.9 50.0
4 165 9.2 38.3
3 279 7.3 4 163 63.4 28.5
5 94 36.6 13.1
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(0.85/0.82); and overall (0.62/0.61). On average, absolute
discriminatory power improved considerably with 5L
(mean 1.87 for 5L versus 1.24 for 3L), and relative dis-
criminatory power improved slightly (mean 0.81 for 5L
versus 0.78 for 3L), confirming our hypothesis.
There is evidence of convergent validity of 3L and 5L
with the WHO-5 (Table 6). All Spearman rank order coef-
ficients for 3L and 5L comparisons with the five WHO-5
items were significant (p \ 0.001). Correlations were
highest for Anxiety/Depression, especially with feeling in
good spirits (3L = 0.55; 5L = 0.57) and feeling calm and
relaxed (3L = 0.61; 5L = 0.61), as expected. High corre-
lations were also found between Mobility, Self-Care,
and Usual Activities with feeling active and vigorous
(‘‘Energy’’), showing correlation coefficients over 0.50
except for 3L Mobility (0.43). The 5L dimensions demon-
strated slightly better convergent validity compared with 3L,
with the largest difference observed for Mobility. Correla-
tions with the WHO-5 sum-scores were 0.49 for 3L on
average (ranging from 0.39 for Mobility to 0.58 for Anxiety/
Depression) and 0.53 for 5L on average (ranging from 0.48
for Pain/Discomfort to 0.58 for Anxiety/Depression). Con-
vergence of 3L and 5L with dimension-specific rating scales
improved slightly with 5L over 3L (mean Spearman’s rho
0.80 versus 0.77, respectively).
Results for known-groups validity are shown in Table 7
and confirmed our hypotheses. All 3L and 5L correlations
with age are significant and in the expected direction,
showing increased reported problems for each dimension
with increasing age, except for Anxiety/Depression which
shows slightly less reported problems with increasing age.
Results for education were similar, showing significantly
less reported problems with higher education, except for
Anxiety/Depression (nonsignificant). Correlations were
generally similar for 5L and 3L. Kruskall–Wallis tests
showed significant results for all dimensions except 3L
Pain/Discomfort. The percentage proportions showed
increasing reported problems going from nonsmokers to
ex-smokers and smokers as expected. The analyses for
clustering showed that for age all comparisons were still
significant, although the p values were higher(range
0.004–0.041). For education and smoking cluster analyses
resulted in nonsignificant results for all 3L and 5L
dimensions. When performing analyses for the separate
countries on education, Scotland showed significant results
for all 3L and 5L dimensions, England showed significant
for all 3L and 5L dimensions except Self-Care and Anxi-
ety/Depression, and Denmark showed nonsignificant

















13.1 8.0 5.2 39.4
COPD/Asthma 8.5 7.0 1.5 17.2
Depression 12.0 6.4 5.6 46.7
Diabetes 33.9 28.3 5.7 16.7
Liver disease 38.5 35.7 2.8 7.2
Personality
disorder
7.7 3.9 3.8 48.8
RA/Arthritis 6.5 1.9 4.6 70.8
Stroke 7.1 6.0 1.1 15.0
Students 47.0 34.3 12.6 26.9
Country
Denmark 32.8 30.4 2.3 7.1
England 10.0 5.7 4.3 43.0
Italya 38.5 35.7 2.8 7.2
Netherlands 7.8 4.0 3.8 49.0
Poland 23.6 17.6 6.0 25.4
Scotland 9.6 6.0 3.6 37.5
Total 20.2 16.0 4.2 20.8
COPD chronic obstructive pulmonary disease, RA rheumatoid
arthritis
a Identical to liver disease cohort
Table 6 Convergent validity: 3L and 5L dimensions with WHO-5 (Spearman rank order coefficients*)
WHO-5 Good spirits Relaxed Energy Fresh and rested Interested in things
EQ-5D 3L 5L 3L 5L 3L 5L 3L 5L 3L 5L
Mobility 0.27 0.39 0.24 0.34 0.43 0.54 0.30 0.33 0.27 0.39
Self-Care 0.39 0.44 0.37 0.39 0.51 0.53 0.37 0.39 0.40 0.39
Usual Activities 0.40 0.40 0.36 0.34 0.54 0.59 0.36 0.40 0.39 0.41
Pain/Discomfort 0.35 0.37 0.32 0.35 0.41 0.47 0.36 0.41 0.29 0.29
Anxiety/Depression 0.55 0.57 0.61 0.61 0.39 0.40 0.43 0.43 0.42 0.42
Average 0.39 0.43 0.38 0.41 0.46 0.51 0.36 0.39 0.35 0.38
Substudy for England only (N = 1001)
* All p \ 0.001
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results for all 3L and 5L dimensions. In regard to smoking,
for all 3L and 5L dimensions England showed significant
results and Scotland showed nonsignificant results.
Discussion
The aim of this study was to assess the performance of the 5L,
in comparison with the 3L, in terms of feasibility (missing
values), redistribution properties, ceiling, discriminatory
power (Shannon indices), and convergent validity. The 5L
performed similar in terms of feasibility, showed increased
discriminatory power, slightly improved convergent valid-
ity, and similar known-groups validity. Redistribution was
confirmed, and the ceiling was reduced with 5L.
The frequency proportions of the redistribution showed
varying distributions over the dimensions. As expected, the
healthiest subgroup within dimensions (3L-1 paired with 5L-1)
always showed the largest proportion, since many (treated)
health conditions display no symptoms or problems on a
particular dimension no matter how refined the response scale.
In all dimensions, the 3L-3 and 5L-4 response pair proportion
was large (C 20 %). This supports the inclusion of a fourth
level at this position, as many respondents opted for ‘‘severe
problems’’ on 5L compared to ‘‘extreme problems’’ on 3L–3.
The same applies to the response pair 3L-2 and 5L-2, where
many respondents opted for ‘‘slight problems’’ on 5L com-
pared to ‘‘some/moderate problems’’ on 3L–3, thus supporting
the inclusion of a second level at this position. The response
pair 3L-2 and 5L-4 was smaller than expected for some
dimensions, that is, 9 % for Anxiety/Depression, 12 % for
Pain/Discomfort, and 13 % for Self-Care. It would seem that
for these dimensions, ‘‘some’’ or ‘‘moderate’’ problems on 3L
are better covered by ‘‘slight’’ or ‘‘moderate’’ problems on 5L,
rather than by ‘‘severe’’ problems on 5L.
Due to the lower threshold (i.e., presence of level 5L–2,
‘‘slight’’ problems), we expected a lower ceiling in the 5L
version. There was indeed a significant reduction in the
ceiling for most patient groups. When the absolute reduction
is low but the ceiling is also low, it can be more useful to look
at the percentage reduction. This revealed a considerable
reduction in the current study (e.g., for COPD/asthma, per-
sonality disorder, RA/arthritis, and stroke). For some coun-
tries both the absolute and percentage reduction were rather
low, however, such as in the Danish and Italian patient
samples. It is possible that these are ‘‘true’’ findings: When
respondents have no problems on the five dimensions, they
will report ‘‘no problems’’ no matter how many levels were
added. For the Danish sample, this was supported by the
relatively good health status of the participating patients,
especially those with diabetes who comprised the main part
of the sample. Thus, 39 % of the Danish patients with dia-
betes reported that the severity of their condition was
‘‘mild,’’ 41 % had no diabetic complications, and 32 % rated
their self-perceived health as either ‘‘excellent’’ or ‘‘very
good.’’ The Italian sample consisted wholly of liver disease
patients with few problems on any dimension regardless of
whether the 3L or 5L version was used. Responses for some
of the subgroups in this sample, including chronic hepatitis,
cirrhosis, and patients who received liver transplantation,
might be influenced by effective coping mechanisms to deal
with these long-term conditions.
Extending the EQ–5D descriptive system to a five-level
version resulted in higher absolute discriminatory power
than for the three-level version in all dimensions, as
expected. Surprisingly, relative discriminatory power
(evenness) did not deteriorate in the 5L but was slightly
better than for the 3L version. The high evenness score in
all 5L dimensions indicated that the extra levels were used
efficiently. Convergent validity with WHO-5 improved
with 5L, especially for Mobility, which might be caused by
changing the 3L level ‘‘confined to bed’’ to ‘‘unable to walk
about.’’ Known-groups validity was confirmed for both 5L
and 3L, showing similar results. Cluster analyses had no
impact on the analyses for age but brought the results for
education and smoking into question. Separate analyses for
Table 7 Known-groups validity: 3L and 5L with socio-demographic variablesa
Demographic variable Age-groups (Spearman’s rho) Education (Spearman’s rho) Smokingb (p value)
3L 5L 3L 5L 3L 5L
Mobility 0.44** 0.45** -0.16** -0.20** \.001 \.001
Self-Care 0.32** 0.33** -0.13** -0.13** \.001 \.001
Usual Activities 0.28** 0.27** -0.15** -0.17** \.001 \.001
Pain/Discomfort 0.23** 0.24** -0.15** -0.14** 0.068 \.001
Anxiety/Depression -0.04* -0.06** -0.04 -0.04 \.001 \.001
* p \ 0.05; ** p \ 0.001
a Education was included only in Denmark, England, and Scotland (n = 1,869); smoking status was included in England and Scotland
(n = 1,501)
b Kruskall–Wallis H
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each country confirmed the hypothesis for all countries
again, except for Denmark where education had no impact
and for Scotland where smoking had no impact. For Denmark
this is likely due to a power issue since the mean level
scores all point in the right direction, and the relatively
healthy Danish sample shows a rather homogeneous dis-
tribution, making it harder to find statistically significant
differences. For Scotland possibly the old age of the
respondents and the low reported health status might mask
the effects of smoking.
The results of this study provide evidence of the validity
of the EQ-5D-5L in a range of patient groups across six
countries. Not all measurement properties were tested in
the current study. The Korean version of the EQ-5D-5L has
proved to be reliable in cancer patients [23], but reliability
still needs to be determined for other language versions and
other patient groups. Furthermore, responsiveness to health
changes over time still needs to be assessed. A limitation of
the current study is that since 5L was always tested first,
there may have been an order effect. The order effect could
account for the slightly higher proportion of missing values
for the 3L. A further limitation is that since the study was
mainly conducted in patient population settings, it was not
possible to calculate and apply sampling weights.
Alongside the descriptive classification system, an
important aspect of the EQ-5D is the availability of index-
based value sets. Valuation studies for the 5L are in pro-
gress around the world and are likely to be published in the
near future. Until these studies are finalized, index values
for 5L based on the 3L value sets are available using a
mapping approach, described in detail by van Hout et al.
(2012) and on the EuroQol Web site at www.euroqol.org
[34].
In conclusion, the EQ-5D-5L is a descriptive system
based upon the dimensions of the EQ-5D-3L that demon-
strates valid redistribution, reduced ceiling, and improved
discriminatory power and convergent validity. Future
studies that further examine the properties of the EQ-5D-
5L in specific conditions and patient populations, particu-
larly studies comparing the EQ-5D-5L to the EQ-5D-3L,
are encouraged.
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